Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates

Annovis Bio Inc. (NYSE: ANVS) has announced a live webcast scheduled for June 24, 2025, at 4:30 PM EDT, where President and CEO Maria Maccecchini, Ph.D., will share critical updates on the company's neurodegenerative disease programs. The focus will be on the pivotal Phase 3 trial for early Alzheimer’s disease and recent FDA feedback regarding its Parkinson’s disease program, alongside other key initiatives. This event underscores Annovis Bio's commitment to developing therapies that target multiple neurotoxic proteins, aiming to restore brain function and enhance patients' quality of life.

The webcast is significant for shareholders, patients, and stakeholders interested in the advancements of treatments for Alzheimer’s and Parkinson’s diseases. Annovis Bio's innovative approach to tackling neurodegeneration could pave the way for groundbreaking therapies in a field where effective treatments are urgently needed. The live Q&A session following the presentation offers a unique opportunity for direct engagement with the company's leadership, providing insights into the future direction of its research and development efforts.

Annovis Bio's work is particularly important given the growing global burden of neurodegenerative diseases. Alzheimer’s and Parkinson’s diseases affect millions worldwide, with current treatments offering limited relief. The company's focus on addressing the root causes of neurodegeneration represents a hopeful avenue for patients and families affected by these conditions. The upcoming webcast will likely shed light on the potential impact of Annovis Bio's therapies on the healthcare landscape, making it a key event for those following advancements in medical science and biotechnology.